<PAGE>

                                                                 Exhibit 10.35

                                          
                               DETECTION OF ANALYTES
                     PRODUCT DEVELOPMENT AND LICENSE AGREEMENT


       This Detection of Analytes Product Development and License Agreement 
("Agreement") is signed on June 19, 1998 by and between Cygnus, Inc., a 
Delaware corporation, with its principal place of business at 400 Penobscot 
Drive, Redwood City, California 94063 ("Cygnus"), and E.I. du Pont de Nemours 
& Co., a Delaware corporation, with its principal place of business at 1001 
Market Street, Wilmington, Delaware 19898 ("DuPont").

       WHEREAS, Cygnus has substantial knowledge and expertise in and owns 
certain technology relating to the development, manufacture and sale of 
transdermal monitoring systems;

       WHEREAS, DuPont has substantial knowledge and expertise in and owns 
certain technology relating to the development, manufacture and sale of thick 
film materials commonly referred to as "inks" or "pastes";

       WHEREAS, the parties desire each other's assistance in developing 
certain technologies related to [Confidential Treatment Requested], including 
without limitation transdermal monitoring systems and the use, composition 
and manufacture of thick film materials;

       WHEREAS, the parties desire to provide such development assistance to 
each other; and

       WHEREAS, the parties also desire to enter into a separate supply 
arrangement with respect to Thick Film Materials (as defined below).

       NOW THEREFORE, in consideration of the above premises and the mutual 
covenants contained herein, the parties hereto agree as follows:

1.     DEFINITIONS.  When used in this Agreement, each of the following terms 
shall have the meaning provided below:

       a.      "Development Plan" means the development plan, specifications, 
Milestones and schedule specified in Exhibit A including amendments thereto 
established by the Development Committee pursuant to Section 2.e below.

       b.      "Diagnostics Field" means all applications for the 
[Confidential Treatment Requested] in connection with the diagnosis and 
treatment of disease in humans, including but not limited to diabetes and 
complications of diabetes; however currently available, whether through 
publication or commercialization, invasive diagnostics applications are not 
included within the definition of Diagnostics Field.

       c.      "Initial Milestones" means Milestones established within sixty 
(60) days

<PAGE>

following the Signing Date of this Agreement and includes, without limitation,
[Confidential Treatment Requested].

       d.      "Milestones" means [Confidential Treatment Requested].

       e.      "Parties" means DuPont and Cygnus and, when used in the 
singular, means either of them.

       f.      "Thick Film Technology" means all Technology and improvements 
thereto relating solely to the composition and manufacture of Thick Film 
Materials (but not applications thereof)  (i) arising out of work done by 
either Party in connection with the Project, or (ii) owned or developed by or 
for DuPont and specifically listed by DuPont Product Number on Exhibit C 
attached hereto.

       g.      "Project" means the Development Plan and the collaboration 
between the Parties after the Effective Date of this Agreement.

       h.      "Thick Film Materials" means thick film materials, commonly 
referred to as "inks" or "pastes," such materials [Confidential Treatment
Requested]. 

       i.      "Sensor Technology" means all Technology and improvements 
thereto within the Diagnostics Field other than Thick Film Technology (but 
including, without limitation, all applications of Thick Film Technology) 
arising out of work done by either Party in connection with the Project.   

       j.      "Supply Agreement" means the Supply Agreement signed of even 
date herewith by the Parties.  

       k.      "Technology" means all foreign and domestic patents, patent 
applications, patent rights, know-how, trade secrets, copyrights, trademarks, 
technical data, inventions (whether patentable or not), discoveries, designs, 
specifications, plans, notebooks, works of authorship, techniques, methods, 
regulatory information, compliance information, clinical data, processes, 
test procedures and all other scientific or technical information or 
materials, in whatever form.

       l.      "Transfer Letter" means a document as described in Exhibit B 
attached hereto.

       m.      "Effective Date" of the Agreement is March 22, 1995.

       n.      Signing Date" of the Agreement refers to the date indicated on 
page 1 of the Agreement.
       
2.     PROJECT DEVELOPMENT.

       a.      JOINT PROGRAM.  For a period commencing on the Effective Date and
terminating as provided in Section 7 below, the Parties shall act in good faith
in a joint program to develop at

                                       2

<PAGE>

least one commercial product in the Diagnostics Field with initial work 
limited to detection of glucose levels.  DuPont shall have responsibility for 
development of commercially suitable Thick Film Materials; Cygnus shall have 
responsibility for all other aspects in development of any commercial product 
for use in the Diagnostics Field.  Each Party shall bear its own costs in the 
development.

       b.      DUPONT ASSISTANCE, TECHNICAL SUPPORT AND DEVELOPMENT.  DuPont, 
at its own cost, shall act in good faith with the assistance of Cygnus to (i) 
develop Thick Film Materials and Thick Film Technology, (ii) meet in a timely 
fashion the Milestones set forth in Exhibit A, and (iii) collaborate with and 
assist Cygnus with the Sensor Technology.  DuPont shall provide reasonable 
resources, technical information, and expertise, at its own cost and expense, 
to achieve the Milestones in accordance with the Development Plan.  DuPont 
will keep Cygnus informed of its progress through regular communication 
between the Project Coordinators and through meetings of the Development 
Committee pursuant to Section 2.e below.  The Development Committee shall 
periodically determine the number of DuPont technical personnel assigned to 
the Project. 

       c.      CYGNUS ASSISTANCE, TECHNICAL SUPPORT AND DEVELOPMENT.  Cygnus 
shall act in good faith:  (i) to collaborate with and assist DuPont with the 
development of the Thick Film Materials and Thick Film Technology to 
accomplish the Milestones in accordance with the Development Plan, (ii) to 
provide data and technical support as reasonably requested by DuPont in 
connection with the Thick Film Materials and Thick Film Technology and the 
Project, (iii) to actively develop Sensor Technology, and (iv) to proceed 
promptly toward commercialization of commercial products in the Diagnostics 
Field.  Cygnus, at its own cost and expense, will allocate sufficient 
resources to provide such assistance and support.

       d.      PROJECT COORDINATORS.  Within thirty (30) days after the 
Signing Date of this Agreement, each Party shall designate one (1) individual 
as its representative to coordinate and generally oversee the development 
work and/or assistance to be performed by such Party hereunder and coordinate 
the Project (including but not limited to coordinating the Development 
Committee and meetings specified in Section 2.e below), and shall provide the 
name of such designated individual ("Project Coordinator") to the other Party 
in writing. Each Party shall promptly notify the other Party in writing of 
any change in its Project Coordinator.

       e.      DEVELOPMENT COMMITTEE.  In addition to appointing Project 
Coordinators, the Parties will form a development committee (the "Development 
Committee") to monitor the progress of the Project development efforts 
referred to in this Section 2.  Within sixty (60) days after the Signing Date 
of this Agreement, the Development Committee shall establish a detailed 
Development Plan which shall include the Initial Milestones, and which shall 
be deemed attached hereto as Exhibit A.  For each Initial Milestone and 
subsequently introduced Milestone added to Exhibit A, the Development 
Committee shall specify the Thick Film Material(s) to which such Milestone 
pertains.  Through the Development Committee, the Parties may establish 
additional Milestones and discuss and decide issues related to the Project, 
including, without limitation, technical issues, scheduling issues and cost 
issues arising from the above activities. Furthermore, the Development 
Committee may amend Exhibit C to include or substitute other

                                       3

<PAGE>

DuPont Product Numbers, if it is in the best interests of the Parties to do 
so.  The Development Committee shall also control, govern, and determine 
access to, release and exchange of technical information and data between the 
Parties and for purposes of regulatory applications and compliance. The 
Development Committee shall also decide when, during the process of 
development of a Thick Film Material, it is necessary for DuPont to prepare 
and maintain a Transfer Letter, which will contain information known by 
DuPont at that time and which will be periodically updated if the Development 
Committee so determines as more information becomes available, and to conduct 
an on-site demonstration for Cygnus of the relevant processes.  If, however, 
a Thick Film Material is in the scale-up or pre-commercialization phase, a 
Transfer Letter shall be manditorily prepared and maintained by DuPont and an 
on-site demonstration shall be conducted for Cygnus.  The Development 
Committee shall consist of an equal number of up to three (3) employees of 
each Party, including at a minimum for each Party, the Project Coordinator 
which may be a senior manager intimately involved with the subject matter of 
this Agreement. The Development Committee shall meet quarterly (or more 
frequently should the Development Committee decide such frequency is 
desirable), alternating between DuPont's and Cygnus' facilities.  Each Party 
shall be responsible for the costs of its employees' attendance at meetings 
of the Development Committee.  All decisions of the Development Committee 
shall require the consent of both Parties.  Any disputes that cannot be 
resolved by the Development Committee shall be escalated for resolution to 
the President of Cygnus Diagnostics and the Director, Worldwide Microcircuit 
Materials of DuPont, or equivalent thereof.

       f.      Neither Party shall have any further obligations under this 
Section 2 provided Cygnus purchases in commercial quantities Thick Film 
Material from DuPont under any obligations it may have under the separate 
Supply Agreement and DuPont has met all Milestones set forth in Exhibit A.  
However, following such Cygnus purchases and DuPont meeting the Milestones, 
the Parties agree to discuss whether to continue additional development and 
cooperation obligations under this Section 2 (and to amend the Agreement 
accordingly) for any additional development projects or improvements to the 
Thick Film Materials. 

       g.      SITE VISITS.  For purposes of reviewing progress of the 
Project, the Parties may facilitate an exchange of technical personnel to 
work on-site at each other's facilities.  Either Party shall be free to visit 
those portions of the facilities of the other Party where work on the Project 
is being conducted. Such visits shall be at reasonable intervals following 
reasonable notice during regular business hours.  DuPont shall pay the 
expenses of its staff visiting Cygnus; Cygnus shall pay the expenses of its 
staff visiting DuPont.  Each Party shall indemnify and hold the other Party 
harmless from and against any liability arising from the activities of its 
employees in the other Party's facilities.

       h.      PROJECT DELAYS.  If at any time during the course of the 
Project, DuPont anticipates that it will not be able to complete a Milestone 
by the date set forth on Exhibit A (or applicable date established by the 
Development Committee) despite DuPont's good faith efforts to do so, DuPont 
shall so notify Cygnus in writing specifying the reasons for delay.  From and 
after such notice, the Parties shall cooperate and use diligent efforts to 
solve the problems identified.  Such Project Delays shall not constitute a 
breach of this Agreement under Section 7.c.

                                      4

<PAGE>

       i.      TRANSFER OF TECHNICAL INFORMATION.  The Parties shall act in 
good faith to freely share with each other technical information in 
connection with their respective Thick Film Technology and Sensor Technology 
and other technical information in connection with the Project, including, 
without limitation, information necessary to enable a Party to file a patent 
application and information necessary to enable Cygnus to obtain FDA approval.

       j.      TECHNICAL ASSISTANCE.  DuPont, at no cost to Cygnus, will 
provide a reasonable level of technical support to Cygnus and Cygnus' 
subcontractors to ensure the Thick Film Materials can be printed effectively.

       k.      SUPPLY OF THICK FILM MATERIALS TO CYGNUS.  Any supply of Thick 
Film Material by DuPont and purchase of such Material by Cygnus shall be 
governed by a separate Supply Agreement, provided that each Thick Film 
Material developed pursuant to a Milestone under the Development Plan shall 
be made available to Cygnus for purchase under the terms of the Supply 
Agreement.

       l.      RIGHT OF FIRST REFUSAL.  During the term of this Agreement, 
DuPont shall have a right of first refusal to participate in any additional 
development projects of Cygnus relating to Thick Film Materials in the 
Diagnostics Field.  Cygnus shall inform DuPont in writing of each new Thick 
Film Material or Milestone which Cygnus intends to develop or have developed 
during the term of this Agreement, and Cygnus shall give DuPont a written 
notice setting forth the specifications for each such development project.  
Cygnus shall offer DuPont the right to develop each new Thick Film Material 
subject to the terms and conditions of this Agreement.  If DuPont does not 
respond or DuPont and Cygnus are unable to agree in good faith upon the 
applicable milestones, specifications or other terms and conditions for the 
development project within sixty (60) days of Cygnus' written notice, then 
Cygnus shall be free to offer the development project to a third party 
developer.  The failure of DuPont to agree to undertake any specific new 
development project shall not affect its rights of first refusal under this 
paragraph for any subsequent development project.  It is understood that any 
additional development project of Cygnus relating to Thick Film Materials 
pursuant to this paragraph shall involve the following:

               (i)    a Thick Film Material which substantially differs 
chemically to reduce cost from a Thick Film Material supplied by DuPont 
pursuant to this Agreement; and

               (ii)   a Thick Film Material which substantially differs in 
performance from a Milestone of this Agreement;

provided, however, that "substantially differs," as used above, means an 
improvement in cost and performance of ten percent (10%) or more.

3.     OWNERSHIP, LICENSE GRANTS AND AGREEMENT NOT TO SUPPLY.

       a.      OWNERSHIP AND ASSIGNMENT OF THICK FILM TECHNOLOGY.  As between
the Parties, DuPont shall own all rights, title, and interest, in and to all of
the Thick Film Materials and Thick

                                       5

<PAGE>

Film Technology both within and outside of the Diagnostics Field, including, 
without limitation, all inventions consisting of the Thick Film Technology 
which were  discovered or developed by or for either or both of the Parties 
in connection with the Project.  Cygnus hereby assigns to DuPont all rights, 
title and interest it may obtain in and to the Thick Film Technology 
throughout the world including, without limitation, any and all related 
patents and patent applications.  Cygnus agrees to assist DuPont (at DuPont's 
request and expense) in every proper way to evidence and perfect the 
foregoing assignment and to apply for patent applications concerning the 
assigned intellectual property rights.  Cygnus will promptly execute, and 
will cause its employees and consultants to execute, applicable documents and 
promptly provide reasonable information (including, without limitation, 
information necessary or appropriate for use in connection with preparation 
of patent applications) that DuPont may request for such purposes; DuPont 
will bear the reasonable out-of-pocket expenses incurred by Cygnus in 
providing such requested assistance.

       b.      [Confidential Treatment Requested] SUPPLY OF THICK FILM MATERIALS
IN THE DIAGNOSTICS FIELD.  Provided that, subject to the terms and conditions of
the separate Supply Agreement between the parties, Cygnus meets its obligations
to purchase from DuPont Cygnus' requirements of Thick Film Materials for a
minimum of [Confidential Treatment Requested], DuPont will not, during and for
an additional period of [Confidential Treatment Requested] after the term of
this Agreement, supply or license the Thick Film Materials or Thick Film
Technology to a third party for use within the Diagnostics Field. 

       c.      OWNERSHIP AND ASSIGNMENT OF SENSOR TECHNOLOGY.  As between the
Parties, Cygnus shall own all rights, title, and interest, in and to all of the
Sensor Technology, including, without limitation, all inventions consisting of
the Sensor Technology which were discovered or developed by or for either or
both of the Parties in connection with the Project.  DuPont hereby assigns to
Cygnus all rights, title and interest it may obtain in and to the Sensor
Technology throughout the world including, without limitation, any and all
related patents and patent applications.  DuPont agrees to assist Cygnus (at
Cygnus' request and expense) in every proper way to evidence and perfect the
foregoing assignment and to apply for patent applications concerning the
assigned intellectual property rights.  DuPont will promptly execute, and will
cause its employees and consultants to execute,  applicable documents and
promptly provide reasonable information (including, without limitation,
information necessary or appropriate for use in connection with preparation of
patent applications) that Cygnus may request for such purposes; Cygnus will bear
the reasonable [Confidential Treatment Requested] incurred by DuPont in
providing such requested assistance.

       d.      PATENT RIGHTS.

               (i)    CYGNUS PATENT RIGHTS.  Cygnus shall be responsible for
and shall control the preparation, filing, prosecution, grant and maintenance of
all patent applications and rights with respect to the Diagnostics Field other
than patent applications solely for the composition and manufacture of Thick
Film Materials.  DuPont shall provide to Cygnus or Cygnus' authorized attorneys,
agents or representatives reasonable assistance to enable Cygnus to file patent
applications with respect to Sensor Technology and the use of Thick Film
Materials in the

                                       6

<PAGE>

Diagnostics Field.  DuPont shall sign or cause to have signed appropriate 
documents relating to said patent applications at no charge to Cygnus.

               (ii)   DUPONT PATENT RIGHTS.  DuPont shall be responsible for 
and shall control the preparation, filing, prosecution, grant and maintenance 
of all patent applications and rights relating solely to the composition and 
manufacture of Thick Film Materials.  Cygnus shall provide to DuPont or 
DuPont's authorized attorneys, agents or representatives reasonable 
assistance to enable DuPont to file patent applications with respect to the 
composition and manufacture of Thick Film Materials.  Cygnus shall sign or 
cause to have signed appropriate documents relating to said patent 
applications at no charge to DuPont.

               (iii)  PATENT APPLICATION COOPERATION.  After the Signing 
Date, at least fourteen (14) days prior to filing any patent application 
relating to the Sensor Technology or Thick Film Technology during the term of 
this Agreement, each Party agrees to provide the other Party (the "Receiving 
Party") a substantially complete draft of such patent application.  Should 
the Receiving Party determine in good faith that such proposed patent 
application claims or discloses Technology owned by the Receiving Party or 
raises strategic filing issues related to such Technology, and the Receiving 
Party communicates such determination in writing before seven (7) days prior 
to the proposed filing date, the Parties shall thereafter decide in good 
faith the ownership interests and filing strategies therein before such 
filing.  If the Receiving Party does not so communicate within such seven (7) 
day period, the other Party may file such application without further 
obligation to the Receiving Party regarding such application.  Any disputes 
regarding this Section 3.d.iii that cannot be resolved by the Development 
Committee shall be escalated for resolution to the President of Cygnus 
Diagnostics and the Director, Worldwide Microcircuit Materials of DuPont, or 
equivalent thereof.  

4.     PUBLICATION

               NOTICE OF PUBLICATION.  During the term of this Agreement, the 
Parties each acknowledge the other Party's interest in publishing certain of 
its results to obtain recognition within the scientific community and to 
advance the state of scientific knowledge.  Each Party also recognizes the 
mutual interest in obtaining valid patent protection and protecting business 
interests. Consequently, after the Signing Date, either Party, its employees 
or consultants wishing to make a publication (including, without limitation 
any oral presentation) made without any obligation of confidentiality (a 
"Disclosure") relating to work performed by either Party as part of the 
Project ("Publishing Party") shall transmit to the other Party ("Reviewing 
Party") a copy of the proposed Disclosure at least thirty (30) days prior to 
submission for publication, or an outline of such oral disclosure at least 
thirty (30) days prior to presentation.  The Reviewing Party shall have the 
right (a) to propose modifications to the publication for patent or other 
reasonable commercial reasons and (b) to request a reasonable delay in 
publication in order to protect patentable information.  If the Reviewing 
Party requests such a delay, the Publishing Party shall delay submission or 
presentation of the publication for a period of not more than sixty (60) days 
to enable patent applications protecting each Party's rights in such 
information to be filed in accordance with Section 3.d above.  For any 
Disclosure, the Project Coordinators or any designee of the Project 
Coordinators shall collaborate in good faith to determine authorship of

                                      7

<PAGE>

any such Disclosure.  In the case of any such Disclosure, upon the expiry of 
thirty (30) days from transmission to the Reviewing Party, the Publishing 
Party shall be free to proceed with the Disclosure unless the Reviewing Party 
has requested the delay described above.  Any disputes as to authorship that 
cannot be resolved by the Project Coordinators or their designees shall be 
escalated for resolution to the Development Committee.  

5.     REPRESENTATIONS AND WARRANTIES

       a.      BY CYGNUS.  Cygnus represents and warrants to DuPont that this 
Agreement has been duly authorized, executed and delivered by Cygnus and 
constitutes a valid and binding obligation of Cygnus, enforceable in 
accordance with its terms.

       b.      BY DUPONT.  DuPont represents and warrants to Cygnus that this 
Agreement has been duly authorized, executed and delivered by DuPont and 
constitutes a valid and binding obligation of DuPont enforceable in 
accordance with its terms.

       c.      BY BOTH.  Each Party represents and warrants to the other 
that, to the best current knowledge of the Party making the representation, 
the Sensor Technology (in the case of Cygnus) or the Thick Film Technology 
(in the case of DuPont), when used in accordance with the assignments and 
licenses granted under this Agreement, does not infringe any valid and 
enforceable patent, copyright, trade secret or other proprietary right of any 
third party as of the Effective Date of this Agreement.

6.     CONFIDENTIALITY.

       a.      Each Party shall, for a period of ten (10) years following the 
date of each disclosure by the other Party, keep confidential and not use for 
other than the purposes of this Agreement, any information disclosed by a 
Party and designated confidential.  Such disclosures, other than in writing, 
shall be confirmed in writing within thirty (30) days of disclosure and 
marked confidential.  However, this provision shall not apply to information 
which:

               (i)    is or has become readily publicly available through no 
fault of the receiving Party or its employees or agents; or

               (ii)   is received from a third party lawfully in possession 
of such information and lawfully empowered to disclose such information and 
provided the receiving Party abides by all restrictions, if any, imposed by 
such third party; or

               (iii)  was rightfully in the possession of the receiving Party 
prior to its disclosure by the other Party;
               
               (iv)   was independently developed by or for employees or 
consultants of the receiving Party without use of or access to confidential 
information of the disclosing Party; or
       
               (v)    is necessary in the filing of any patent application; or

                                       8

<PAGE>

               (vi)   is deemed reasonably necessary by DuPont in the 
commercialization of Thick Film Materials or by Cygnus in the 
commercialization of product for use in the Diagnostics Field, so long as 
such Party has the prior written approval of the other Party prior to 
disclosing or disseminating such information, such approval not to be 
unreasonably withheld.

Notwithstanding the foregoing, the receiving Party may disclose confidential 
information to the extent it is required to be disclosed to a governmental 
entity or agency in connection with seeking any governmental or regulatory 
registration, approval or license, or pursuant to the lawful requirement or 
request of a governmental entity or agency, provided that reasonable measures 
are taken to obtain confidential treatment thereof and to guard against 
further disclosure.

       b.      The confidentiality obligations of both Parties set forth in a 
Confidentiality Agreement originally accepted on March 22, 1995 by Cygnus 
Therapeutic and extended effective March 21, 1996 signed by Cygnus, Inc. 
shall be governed by the present Agreement and this earlier Confidentiality 
Agreement, as amended and extended, is hereby terminated.

7.     TERM AND TERMINATION.

       a.      TERM.  This Agreement will commence as of the Effective Date 
and, unless terminated as provided below, shall continue in effect for 
[Confidential Treatment Requested].

       b.      Either Party may terminate this Agreement at any time by 
providing the other Party with sixty (60) days' prior written notice.

       c.      Either Party may terminate this Agreement upon sixty (60) 
days' written notice if there has been a material breach of any 
representation, warranty, covenant or obligation contained in this Agreement 
on the part of the other Party which such Party fails to cure during such 
sixty day period; provided that, notwithstanding anything else to the 
contrary, the terminating Party will not be obligated to continue development 
work after it gives notice of termination unless the breach is timely cured 
during such period.

       d.      Either Party may terminate this Agreement if the other ceases 
to do business, or otherwise terminates its business operations.

       e.      Either Party may terminate this Agreement if the other shall 
seek protection under any bankruptcy, receivership, trust deed, or comparable 
proceeding, or if any such proceeding is instituted against the other (and 
not dismissed within one hundred and eighty (180) days).

       f.      DuPont may terminate this Agreement by giving Cygnus written 
notice in the event of:

               (i)    notice from any source to DuPont of any allegation
relating to the Thick Film Materials or monitoring system using such Thick Film
Materials that, in

                                       9

<PAGE>

DuPont's sole discretion, may raise an issue or a controversy relating to the 
safety of such Thick Film Materials or monitoring system using such Thick 
Film Materials, or
               
               (ii)   notice from any source to DuPont of any allegation 
of personal injury that in DuPont's sole discretion, may raise an issue or a 
controversy relating to the safety of the Thick Film Materials or the 
monitoring system using such Thick Film Materials.

       g.      In the event DuPont provides written notice of its termination 
of this Agreement under Section 7.b or if Cygnus terminates this Agreement 
for cause under Sections 7.c, 7.d, or 7.e:
       
               (i)    DuPont shall, at the prompt written request of Cygnus, 
immediately provide Cygnus or its designee a Transfer Letter detailing all 
information necessary for Cygnus or its designated third party to manufacture 
to specifications (as set forth in the Transfer Letter) the Thick Film 
Materials applicable to the Diagnostics Field under this Agreement and take 
all reasonable steps to assist Cygnus in such a transfer, provided Cygnus 
pays DuPont for DuPont's reasonable actual, direct costs in the transfer of 
Technology; additionally, provided Cygnus places an order within sixty (60) 
days from receipt of Transfer Letter, DuPont shall sell Cygnus up to eighteen 
(18) months' supply of Thick Film Materials; 
               
               (ii)   Cygnus shall be free to use any confidential 
information it deems necessary in the development and commercialization of 
Thick Film Materials for use in the Diagnostics Field, without any prior 
approval of DuPont; and 
               
               (iii)  DuPont shall perform either one of the following at 
DuPont's sole discretion:

                      A.  grant Cygnus an [Confidential Treatment Requested]
license in the Diagnostics Field, with the right to sublicense, under 
DuPont's patents and patent applications relating to Thick Film Materials 
that arise out of work done in connection with the Project or are 
specifically listed on Exhibit C to import, make, have made, use, offer for 
sale and sell in the Diagnostics Field, provided Cygnus pays DuPont's prior 
actual, direct [Confidential Treatment Requested] relating to  such patent 
applications and patents and, provided Cygnus agrees to pay either DuPont's 
future reasonable in-house [Confidential Treatment Requested] or those 
[Confidential Treatment Requested] of a mutually agreed upon law firm, 
whichever is more cost-effective, for prosecuting and maintaining such patent 
applications and patents; or
                      
                      B.  assign promptly DuPont's  patents and patent 
applications relating to Thick Film Materials  applicable to the Diagnostics 
Field that arise out of work done in connection with the Project or are 
specifically listed on Exhibit C, provided Cygnus pays DuPont's prior actual 
direct out-of-pocket costs relating to such patent applications and patents 
and any actual direct out-of-pocket costs relating to the assignment of such 
patent applications and patents.
                      
       h.      In the event only that DuPont provides written notice of its
termination of this

                                      10

<PAGE>

Agreement under Section 7.f:
       
               (i)    DuPont shall, at the prompt written request of Cygnus, 
immediately provide Cygnus or its designee a Transfer Letter detailing all 
information necessary for Cygnus or its designated third party to manufacture 
to specifications (as set forth in the Transfer Letter) the Thick Film 
Materials applicable to the Diagnostics Field under this Agreement and take 
all reasonable steps to assist Cygnus in such a transfer, provided Cygnus 
pays DuPont for DuPont's reasonable actual, direct costs in the transfer of 
Technology; additionally, provided Cygnus places an order within sixty (60) 
days from receipt of Transfer Letter, DuPont shall sell Cygnus up to eighteen 
(18) months' supply of Thick Film Materials; 
               
               (ii)   Cygnus shall be free to use any confidential 
information it deems necessary in the development and commercialization of 
Thick Film Materials for use in the Diagnostics Field, without any prior 
approval of DuPont; and

                (iii) DuPont shall perform one of the following at DuPont's
sole discretion:

                      A.  grant Cygnus an [Confidential Treatment Requested]
license in the Diagnostics Field, with the right to sublicense, under DuPont's
patents and patent applications relating to Thick Film Materials that arise out
of work done in connection with the Project or are specifically listed on
Exhibit C to import, make, have made, use, offer for sale and sell in the
Diagnostics Field, provided Cygnus pays DuPont's prior actual, direct
[Confidential Treatment Requested] relating to such patent applications and
patents and, provided Cygnus agrees to pay either DuPont's future reasonable
in-house [Confidential Treatment Requested] or those [Confidential Treatment
Requested] of a mutually agreed upon law firm, whichever is more cost-effective,
for prosecuting and maintaining such patent applications and patents;

                      B.  assign promptly DuPont's patents and patent
applications relating to Thick Film Materials applicable to the Diagnostics
Field that arise out of work done in connection with the Project or are
specifically listed on Exhibit C, provided Cygnus pays DuPont's prior actual
direct out-of-pocket costs relating to  such patent applications and patents and
any actual direct out-of-pocket costs relating to any assignment of such patent
applications and patents; or
                      
                      C.  agree that it will not assert any patent or patent
application controlled (in the sense of having the right to grant licenses and
sublicenses) by DuPont corresponding in subject matter to the Thick Film
Technology to prevent any party, including Cygnus, from importing, making,
having made, using, offering to sell, or selling any product for use in the
Diagnostics Field.

       i.      In the event that Sections 7.g.i or 7.h.i are exercised, Cygnus
shall indemnify, defend, and hold DuPont harmless from all claims for
compensatory or punitive damages arising from personal injury, wrongful death,
property damage, or any other type of damages associated with the transferred
Thick Film Materials and/or Thick Film Technology, whether claims are

                                      11

<PAGE>

based on any alleged:  breach of a contractual obligation; violation of any 
statute or regulation; or tortious conduct, including but not limited to, 
claims of negligence, strict liability, concert of action, conspiracy, third 
party contractor claims, or allegations of DuPont's joint or sole negligence 
or other tortious conduct associated with the transferred Thick Film 
Materials and/or Thick Film Technology; provided, however, such indemnity 
shall apply to Thick Film Materials made by DuPont and transferred to Cygnus 
under Sections 7.g.i or 7.h.i only insofar as such Thick Film Materials meet 
specifications and warranties, both of which are delineated in the Supply 
Agreement.
 
       j.      Termination of this Agreement shall not terminate Section 3 in 
its entirety and the obligations of publication clearance pursuant to Section 
4, those obligations of confidentiality pursuant to Section 6, the 
termination provisions of Section 7, and general requirements of Section 8.

8.     GENERAL.

       a.      AMENDMENT AND WAIVER.  Except as otherwise expressly provided 
herein, any provision of this Agreement may be amended and the observance of 
any provision of this Agreement may be waived (either generally or in any 
particular instance and either retroactively or prospectively) only with the 
written consent of both Parties.  However, it is the intention of the Parties 
that this Agreement be controlling over additional or different terms of any 
purchase order, confirmation, invoice or similar document, even if accepted 
in writing by both Parties, and that waivers and amendments of any provision 
of this Agreement shall be effective only if made by non-pre-printed 
agreements signed by both Parties and clearly understood by both Parties to 
be an amendment or waiver. The failure of either Party to enforce its rights 
under this Agreement at any time for any period shall not be construed as a 
waiver of such rights.

       b.      GOVERNING LAW AND LEGAL ACTIONS.  This Agreement shall be 
governed by and construed under the laws of the State of California and the 
United States without regard to conflict of laws provisions thereof.  In any 
action or proceeding to enforce rights under this Agreement, the prevailing 
Party shall be entitled to recover costs and attorneys' fees.

       c.      HEADINGS.  Headings and captions are for convenience only and 
are not to be used in the interpretation of this Agreement.

       d.      NOTICES.  Any notice or other communication required or 
permitted to be made or given to either Party under this Agreement shall be 
deemed sufficiently made or given on the date of delivery if delivered in 
person or by overnight commercial courier service with tracking capabilities 
with costs prepaid, or three (3) days after the date of mailing if sent by 
certified first class U.S. mail, return receipt requested and postage 
prepaid, at the address of the Parties set forth below or such other address 
as may be given from time to time under the terms of this notice provision:

       If to DuPont:

                                      12

<PAGE>

       DuPont Photopolymer & Electronic Materials
       E.I. du Pont de Nemours and Company
       14 TW Alexander Drive
       P.O. Box 13999
       Research Triangle Park, NC 27709-3999
       Attention: Director, Worldwide Microcircuit Materials

       If to Cygnus:

       Cygnus, Inc.
       400 Penobscot Drive
       Redwood City, California 94063
       Attention: President, Cygnus Diagnostics

       e.      ENTIRE AGREEMENT.  This Agreement (and all Exhibits hereto) 
constitutes the entire understanding and agreement with respect to the 
subject matter hereof and supersedes all proposals, oral or written, all 
negotiations, conversations, or discussions between or among the Parties 
relating to the subject matter of this Agreement and all past dealing or 
industry custom.

       f.      SEVERABILITY.  If any provision of this Agreement is held to 
be illegal or unenforceable, that provision shall be limited or eliminated to 
the minimum extent necessary so that this Agreement shall otherwise remain in 
full force and effect and enforceable.

       g.      RELATIONSHIP OF PARTIES.  The Parties hereto expressly 
understand and agree that the other is an independent contractor in the 
performance of each and every part of this Agreement, is solely responsible 
for all of its employees and agents and its labor costs and expenses arising 
in connection therewith.

       h.      ASSIGNMENT.  This Agreement and the rights hereunder are not 
transferable or assignable without the prior written consent of the Parties 
hereto, except for rights to payment and except to a person or entity who 
acquires all or substantially all of a Party's stock, assets or business to 
which this Agreement pertains, whether by sale, merger, acquisition or 
otherwise.

       i.      PUBLICITY AND PRESS RELEASES.  Except to the extent necessary 
under applicable laws or for ordinary marketing purposes, the Parties agree 
that no press releases or other publicity relating to the substance of the 
matters contained herein will be made without approval by both Parties.  Any 
press release announcing this Agreement will be jointly developed and 
released by the Parties.

       j.      FORCE MAJEURE.  No liability or loss of rights hereunder shall 
result to either Party from delay or failure in performance caused by an 
event of force majeure (that is, circumstances beyond the reasonable control 
of the Party affected thereby, including, without limitation, acts of God, 
fire, flood, war, government action, compliance with laws or regulations 
(including, without limitation, those related to infringement), strikes, 
lockouts or other serious labor disputes, or shortage of or inability to 
obtain material or equipment) for so long as such event of

                                      13

<PAGE>

force majeure continues in effect.

       k.      REMEDIES.  Except as otherwise expressly stated in this 
Agreement, the rights and remedies of a Party set forth herein with respect 
to failure of the other to comply with the terms of this Agreement 
(including, without limitation, rights of full termination of this Agreement) 
are not exclusive, the exercise thereof shall not constitute an election of 
remedies and the aggrieved Party shall in all events be entitled to seek 
whatever additional remedies may be available in law or in equity.

       l.      COMPLIANCE WITH LAW; EXPORT CONTROL.  Each party agrees to 
comply with the U.S. Foreign Corrupt Practices Act (regarding among other 
things, payments to government officials) and all export laws, restrictions, 
national security controls and regulations of the United States or other 
applicable foreign agency or authority, and not to export or re-export, or 
allow the export or re-export of any Confidential Information or any copy or 
direct product thereof in violation of any such restrictions, laws or 
regulations, or to any Group D:1 or E:2 country (or any national of such 
country) specified in the then current Supplement No. 1 to Part 740, or, in 
violation of the embargo provisions in Part 746, of the U.S. Export 
Administration Regulations (or any successor regulations or supplement), 
except in compliance with and with all licenses and approvals required under 
applicable export laws and regulations, including without limitation, those 
of the U.S. Department of Commerce.

       IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as 
of the date indicated on the first page of this Agreement.

CYGNUS, INC.                     E.I. DU PONT DE NEMOURS & CO.

By:  /s/ Gregory B. Lawless           By: /s/ J. Stan Erickson
   ----------------------------          --------------------------------------
Name:  Gregory B. Lawless             Name:  J. Stan Erickson
                                           ------------------------------------
Title: President and Chief            Title:  Worldwide Business Development
       Executive Officer                      ---------------------------------
                                              Director - Microcircuit Materials


                                      14

<PAGE>

                                 EXHIBIT A
                              DEVELOPMENT PLAN
                     [Confidential Treatment Requested]

   Milestones                              Associated Thick Film Material(s)
   ----------                              ---------------------------------
                                                    (per Milestone)




                                      15

<PAGE>

                                  EXHIBIT B
                        CONTENTS OF TRANSFER LETTER
                          FOR THICK FILM MATERIALS
                                      
[Confidential Treatment Requested]



                                     16

<PAGE>

                                      
                                 EXHIBIT C
                        DUPONT THICK FILM MATERIALS
                                      
[Confidential Treatment Requested]



                                     17